Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)

Regenxbio Inc. delivered a strong quarter, driven by milestone revenue, with GAAP EPS of $0.43 and revenue up 407% YoY. RGNX now holds $313 million in pro forma cash, funding operations into Q4 2027 and removing near-term financing overhang. Multiple late-stage catalysts—including RGX-202, pivotal wet AMD data, and RGX-121 resubmission—are stacked over the next 12–18 months. Valuation embeds partial pipeline success but not full de-risking; execution on upcoming clinical milestones is key for re-rating potential.

Regenxbio Inc. ( RGNX ) reported a pretty strong headline quarter . GAAP EPS came in at $0.43, beating by about $0.42, and revenue reached $108.0 million, a figure up 407% YoY and beating the consensus by $11.6 million. However, the bulk of the